A father of two boys with Duchenne muscular dystrophy is running the Austin Marathon to raise funds toward pursuit of a cure for the rare, fatal disease.
The free Patient-Centric Trial Development Toolkit is aimed toward helping sites and sponsors identify and minimize risks in rare-disease clinical studies.
The advanced biotech analysis company is harnessing the power of a formidable supercomputer to discover potential treatments for the virus and mutations.
Artificial intelligence software company Thirona has released PRAGMA-AI, technology that automates and accelerates CT scans in cystic fibrosis analysis.
A couple of new developments to report in relation to Merck, known as MSD outside the US and Canada: the first being the rejection by the US FDA of the company’s application to use its anti-PD-1 therapy, Keytruda, in certain breast cancer patients.
According to a Veeva Systems survey, contract research organizations are working to ensure clinical trials keep going during the COVID-19 era and beyond.
A representative of the rare-disease specialist firm outlines the unique obstacles of orphan CNS disease research, and how professionals can overcome them.
A survey by the Pistoia Alliance indicates most professionals believe the tech can accelerate R&D, but companies are stymied by a skills gap and data bias.
The two companies will work together to evaluate the combination of SLC-391 and Keytruda in treating patients with advanced non-small cell lung cancer.
Two experts from CRO Phastar talk about how trial professionals face new, ever-changing challenges regarding collecting and disseminating patient data.
The company’s Patient Advisory Council brings together a range of people and perspectives to help ensure increased diversity, inclusivity and engagement.
The company reports that its patient-centric virtual study technology currently is in use in more than 60 ongoing trials in over 40 different countries.
Health Union offers patients dealing with a range of conditions ways to connect with valuable information, research opportunities and each other online.
A new report from the organization forecasts a wave of pharma innovation over the next four years could lead to 75 FDA drug approvals annually by 2025.
The results of a recent Phase III study show caregivers can gauge by individual age, functional status to adapt treatment approaches to specific patients.
The companies are joining on a hybrid clinical trial to test a potential COVID-19 treatment, featuring an ambitious remote patient monitoring strategy.
As the vaccine goes into the arms of more people around the country, the US agency keeps on top of issues around the virus, offering resources and guidance.
Saama’s range of Smart applications will be integrated with the Oracle Health Sciences Clinical One platform to help users accelerate drug development.
The two major pharmaceutical firms have agreed to jointly develop and commercialize treatment combinations of lenacapavir and islatravir in HIV patients.
A leader from the trial solutions provider discusses how the COVID-19 pandemic has accelerated the already growing interest in remote patient monitoring.
Cell and Gene Therapy Catapult (CGT Catapult) says that GSK will leverage its Stevenage facility to perform GMP cell processing and accelerate its cell and gene therapy pipeline for clinical trials.
The Orchestrated Customer Engagement Technology reportedly has been adopted by 140 life sciences companies (including top-10 pharma firms) in nearly 90 countries.
The IQVIA and NORD study shows rare-disease treatments account for only 11% of new drug spending, but 80% of orphan products treat rare diseases alone.
The direct-to-patient service is designed to support trials and help to minimize trial length and costs, while boosting enrollment and participation rates.
Novartis reported today that a clinical trial of the drug, known as canakinumab, when combined with chemotherapy agent, docetaxel, failed to extend the lives of patients with advanced or metastatic non-small cell lung cancer compared to just chemotherapy...
The development technology firm plans to use the funds, sourced from a wide range of investors, to expand its dev-ops platform and expand its global reach.
Valneva and Pfizer have initiated a Phase 2 study for their Lyme disease vaccine candidate: which is the only active Lyme disease vaccine in clinical development today.
The CRO will receive funding to fuel a five-year Research Project Award, with the goal to design and conduct research of potential PTSD treatment options.
The 2020 Pfizer/BioNTech COVID-19 vaccine trial recruited more than 44,000 participants and reached submission for emergency authorization in 248 days: showing unprecedented speed and agility in the context of a global pandemic. So what have been the...
The Verisense Pulse+ can measure heart rate, oxygen saturation, emotional responses, and activity and sleep levels of at-home clinical trial participants.
A leader from the genetic solutions firm explains how genetic testing and counseling can help trial teams form more beneficial connections with patients.
An executive from the rare disease technology solutions company discusses how forcing connections with patients can boost research into such conditions.
A leader from the risk-based quality management solutions provider will discuss the growing interest in the technology, during this year’s SCOPE event.
An executive from the clinical trial technology provider will share how direct data capture can save time, avoid errors and improve the patient experience.
The annual event, moved to the virtual realm thanks to COVID-19, offers content on remote monitoring, drug development technology and other key topics.
The collaboration will leverage patients’ biological and medical data to streamline patient identification and recruitment efforts in clinical research.
